
Germline mutations in HRR pathway genes can increase an individual’s susceptibility to hereditary cancers. The Germline HRR Gene Panel is a comprehensive genetic test, analyzed using Next-Generation Sequencing (NGS), that evaluates key HRR genes to detect variations or pathogenic changes that may predispose individuals to cancer.
This test provides insights into inherited risks for cancers such as breast, ovarian, pancreatic, and prostate cancer. It supports genetic counseling, risk assessment, and personalized treatment decisions, including targeted therapies or preventive interventions. By identifying germline mutations, the panel aids doctors in developing tailored management strategies and guiding family planning decisions for at-risk individuals.
Doctors may recommend the Germline HRR Panel for individuals with a personal or family history of hereditary cancers, early-onset cancers, bilateral cancers, or known genetic risk factors. The test is also useful for patients who wish to understand their inherited risk and plan preventive strategies.
For this test, it is important to submit the clinical history, histopathology report, previous test results, and a doctor’s prescription at the time of sample collection. The Tata 1mg consolidated Test Requisition Form (TRF) must also be duly filled and submitted.
Lab test results may vary across different laboratories. Abnormal test results require an expert interpretation. Therefore, never try to self-medicate at home based solely on these results, and always consult a doctor for proper understanding of the test results.
Note: Genetic counseling can be provided. If interested, please send the request to this email id:[email protected]
The Germline HRR Gene Panel detects inherited (germline) mutations in critical genes involved in the Homologous Recombination Repair (HRR) pathway, which is responsible for repairing DNA damage and maintaining genetic stability. Variations in these genes can compromise DNA repair mechanisms, increasing the risk of developing hereditary cancers.
By analyzing these genes, the test identifies pathogenic or likely pathogenic variants that may predispose an individual to cancers such as breast, ovarian, pancreatic, and prostate cancers. Detecting these mutations not only helps in understanding inherited cancer risk but also allows doctors to recommend appropriate surveillance, preventive measures, or early interventions.
The panel uses Next-Generation Sequencing (NGS) technology, which provides a highly accurate and comprehensive analysis of multiple HRR pathway genes simultaneously. This enables precise risk assessment, supports personalized treatment planning (including targeted therapies), and informs medical decisions for both patients and their families.
In addition, the test results can guide genetic counseling, helping at-risk family members understand their own potential cancer risks and take proactive steps for monitoring or prevention.
The Germline HRR Gene Panel is done:
- If you have a personal or family history of hereditary cancers, especially breast, ovarian, pancreatic, or prostate cancers.
- If your cancer diagnosis occurred at a young age, or you have bilateral cancers.
- To guide personalized treatment decisions, such as targeted therapies or preventive interventions.
- To support genetic counseling and family planning for at-risk individuals.
- To assess inherited risk for developing certain types of cancers and guide regular surveillance.
- Provide your clinical history, previous test reports, and a valid prescription. Tata 1mg consolidated TRF to be filled.





















